You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 15, 2025

CLINICAL TRIALS PROFILE FOR MEXILETINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Mexiletine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000464 ↗ Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1987-04-01 To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000464 ↗ Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) Completed University of Washington Phase 3 1987-04-01 To compare the efficacy of amiodarone to conventional anti-arrhythmic therapy in individuals who had survived one episode of out-of-hospital cardiac arrest.
NCT00000518 ↗ Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1985-07-01 To determine whether electrophysiologic study (EPS) or Holter monitoring (HM) was the better method for selecting effective long-term antiarrhythmic drug therapy in patients with sustained ventricular tachycardia, ventricular fibrillation, or an episode of aborted sudden death.
NCT00000518 ↗ Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) Completed University of Utah Phase 3 1985-07-01 To determine whether electrophysiologic study (EPS) or Holter monitoring (HM) was the better method for selecting effective long-term antiarrhythmic drug therapy in patients with sustained ventricular tachycardia, ventricular fibrillation, or an episode of aborted sudden death.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mexiletine Hydrochloride

Condition Name

Condition Name for Mexiletine Hydrochloride
Intervention Trials
Non-Dystrophic Myotonia 3
Heart Diseases 2
Myotonic Dystrophy 2
Sporadic Amyotrophic Lateral Sclerosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mexiletine Hydrochloride
Intervention Trials
Myotonia 6
Sclerosis 4
Motor Neuron Disease 4
Amyotrophic Lateral Sclerosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mexiletine Hydrochloride

Trials by Country

Trials by Country for Mexiletine Hydrochloride
Location Trials
United States 73
Canada 4
United Kingdom 3
Denmark 3
Netherlands 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mexiletine Hydrochloride
Location Trials
New York 8
Massachusetts 5
California 5
Pennsylvania 4
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mexiletine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Mexiletine Hydrochloride
Clinical Trial Phase Trials
Phase 4 4
Phase 3 8
Phase 2/Phase 3 2
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mexiletine Hydrochloride
Clinical Trial Phase Trials
Completed 22
Not yet recruiting 4
Recruiting 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mexiletine Hydrochloride

Sponsor Name

Sponsor Name for Mexiletine Hydrochloride
Sponsor Trials
Lupin Ltd. 3
University of Washington 3
Grete Andersen, MD 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mexiletine Hydrochloride
Sponsor Trials
Other 35
NIH 6
Industry 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Mexiletine Hydrochloride: Clinical Trials, Market Analysis, and Projections

Introduction

Mexiletine hydrochloride, a sodium channel blocker classified as a Class 1B antiarrhythmic, has been a subject of interest in both clinical and market contexts. Here, we will delve into the current clinical trials, market analysis, and future projections for this drug.

Clinical Trials Update

HERCULES Study

One of the significant ongoing clinical trials is the HERCULES study, a randomized, double-blind, placebo-controlled, multi-center study. This trial aims to investigate the efficacy and safety of once-daily mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2). The study involves a 4-week screening period and a 26-week treatment phase, with approximately 80 DM1 patients and 16 DM2 patients enrolled. The trial includes rigorous inclusion and exclusion criteria to ensure the safety and efficacy of the treatment[1].

N-of-1 Trials for Nondystrophic Myotonia

Another notable study involved a series of aggregated, double-blind, randomized, placebo-controlled N-of-1 trials conducted in patients with nondystrophic myotonia. This study, published in JAMA, showed a significant reduction in mean daily-reported muscle stiffness in patients treated with mexiletine compared to those receiving a placebo. The study highlighted the effectiveness of mexiletine in reducing muscle stiffness and its potential as a treatment for rare muscle disorders[4].

Market Analysis

Current Market Size and Segmentation

The Mexiletine Hydrochloride Tablets Market has experienced rapid growth in recent years. As of 2023, the market size is substantial, and it is anticipated to continue growing significantly until 2031. The market is segmented by type (50mg/tablet, 100mg/tablet) and application (hospital pharmacy, retail pharmacy), with geographical regions including North America, Europe, Asia-Pacific, and others[2].

Key Drivers and Restraints

The growth of the mexiletine hydrochloride market is driven by several factors, including the increasing prevalence of cardiac disorders and muscle diseases, the growing number of clinical trials for novel antiarrhythmic drugs, and rising investments in research and development. However, the market also faces restraints such as stringent regulatory approvals, potential side effects of the drug, and competition from other antiarrhythmic medications[2][5].

Competitive Landscape

The competitive landscape of the mexiletine hydrochloride market includes key players such as CSPC OUYI Pharmaceutical, Shanghai Sine Pharmaceutical Laboratories, Dandong Yichuang Pharmaceutical, Jilin Jinheng Pharmaceutical, and Yangzhou Aidea Pharmaceutical. These companies are actively involved in the production and distribution of mexiletine hydrochloride tablets across various regions[2].

Market Projections

Forecast Period

The mexiletine hydrochloride market is projected to grow significantly from 2024 to 2031. The forecast period indicates a robust growth rate, driven by the increasing demand for antiarrhythmic and myotonia treatments. The market size is expected to reach substantial values by the end of the forecast period, reflecting the optimistic outlook for this segment[2].

Geographical Outlook

North America and Europe are expected to be major contributors to the growth of the mexiletine hydrochloride market, due to the high prevalence of cardiac and muscle disorders in these regions. The Asia-Pacific region is also anticipated to show significant growth, driven by increasing healthcare expenditure and a growing patient population[2].

Economic and Regulatory Factors

The market will be influenced by economic factors such as product pricing, market penetration, and the economic landscapes of various countries. Regulatory factors, including approvals and compliance with safety standards, will also play a crucial role in shaping the market. The analysis using Porter's 5 Forces Framework and macroeconomic analysis will provide deeper insights into these factors[2].

Adverse Events and Safety Considerations

Common Adverse Events

Clinical trials have identified gastrointestinal discomfort as one of the most common adverse events associated with mexiletine, affecting approximately 70% of patients. Other serious adverse events, such as allergic skin reactions, have also been reported, although they are less frequent[4].

Safety Criteria

The HERCULES study and other clinical trials have strict inclusion and exclusion criteria to ensure patient safety. These include monitoring electrolyte imbalances, cardiac safety evaluations, and excluding patients with severe renal impairment or other serious medical conditions[1].

Conclusion

Mexiletine hydrochloride is a drug with significant potential in treating myotonic dystrophy and other muscle disorders, as well as certain arrhythmias. The ongoing clinical trials, such as the HERCULES study, are crucial in establishing its efficacy and safety. The market for mexiletine hydrochloride is expected to grow substantially, driven by increasing demand and advancements in healthcare.

Key Takeaways

  • Clinical Trials: Ongoing trials like the HERCULES study are evaluating the efficacy and safety of mexiletine in patients with myotonic dystrophy.
  • Market Growth: The mexiletine hydrochloride market is projected to grow significantly from 2024 to 2031, driven by increasing demand and research investments.
  • Adverse Events: Common adverse events include gastrointestinal discomfort, with serious events being less frequent.
  • Geographical Outlook: North America and Europe are expected to be major contributors to market growth, with the Asia-Pacific region also showing significant potential.
  • Regulatory and Economic Factors: Market growth will be influenced by regulatory approvals, product pricing, and economic landscapes.

FAQs

What is the primary use of mexiletine hydrochloride?

Mexiletine hydrochloride is primarily used as a sodium channel blocker to treat certain types of arrhythmias and muscle disorders, including myotonic dystrophy.

What are the common adverse events associated with mexiletine hydrochloride?

The most common adverse event is gastrointestinal discomfort, affecting approximately 70% of patients. Serious adverse events, such as allergic skin reactions, are less frequent.

What is the HERCULES study, and what does it aim to achieve?

The HERCULES study is a randomized, double-blind, placebo-controlled, multi-center study aimed at evaluating the efficacy and safety of once-daily mexiletine PR in patients with myotonic dystrophy type 1 and type 2.

How is the mexiletine hydrochloride market segmented?

The market is segmented by type (50mg/tablet, 100mg/tablet) and application (hospital pharmacy, retail pharmacy), with geographical regions including North America, Europe, Asia-Pacific, and others.

What are the key drivers of the mexiletine hydrochloride market growth?

The growth is driven by the increasing prevalence of cardiac and muscle disorders, growing clinical trials for novel antiarrhythmic drugs, and rising investments in research and development.

Sources

  1. ClinicalTrials.gov: "A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study)".
  2. Market Research Intellect: "Mexiletine Hydrochloride Tablets Market Size, Scope And Forecast".
  3. Ozmosi: "Mexiletine Drug Profile".
  4. JAMA Network: "Effect of Mexiletine on Muscle Stiffness in Patients with Nondystrophic Myotonia".
  5. Fortune Business Insights: "Critical Care Antiarrhythmic Drugs Market Size, Share & Report, 2027".
Last updated: 2025-01-03

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.